Aristippos Gennadios Sells 8,325 Shares of Catalent Inc (NYSE:CTLT) Stock

Catalent Inc (NYSE:CTLT) insider Aristippos Gennadios sold 8,325 shares of the company’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $73.00, for a total transaction of $607,725.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

CTLT stock opened at $71.94 on Wednesday. The firm has a market cap of $11.32 billion, a price-to-earnings ratio of 102.77, a PEG ratio of 4.35 and a beta of 1.65. The firm has a 50-day simple moving average of $74.17 and a two-hundred day simple moving average of $60.59. Catalent Inc has a one year low of $31.04 and a one year high of $80.52. The company has a debt-to-equity ratio of 1.34, a quick ratio of 1.58 and a current ratio of 1.90.

Catalent (NYSE:CTLT) last released its quarterly earnings results on Tuesday, May 5th. The company reported $0.50 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.45 by $0.05. The business had revenue of $760.60 million during the quarter, compared to analyst estimates of $696.10 million. Catalent had a net margin of 4.79% and a return on equity of 14.58%. The company’s quarterly revenue was up 23.2% on a year-over-year basis. During the same period in the prior year, the firm posted $0.49 earnings per share. As a group, equities analysts predict that Catalent Inc will post 1.61 earnings per share for the current fiscal year.

A number of research analysts have recently commented on CTLT shares. Zacks Investment Research cut shares of Catalent from a “buy” rating to a “hold” rating in a report on Friday, June 5th. Robert W. Baird increased their target price on shares of Catalent from $74.00 to $80.00 and gave the stock an “outperform” rating in a report on Friday, June 26th. UBS Group increased their target price on shares of Catalent from $70.00 to $77.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. Argus began coverage on shares of Catalent in a report on Thursday, June 25th. They set a “buy” rating on the stock. Finally, Deutsche Bank increased their target price on shares of Catalent from $59.00 to $62.00 and gave the stock a “hold” rating in a report on Wednesday, May 6th. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $74.71.

Hedge funds have recently added to or reduced their stakes in the business. Stephenson National Bank & Trust purchased a new position in shares of Catalent in the 1st quarter valued at approximately $42,000. Shine Investment Advisory Services Inc. raised its position in shares of Catalent by 205.0% in the 1st quarter. Shine Investment Advisory Services Inc. now owns 2,019 shares of the company’s stock valued at $105,000 after purchasing an additional 1,357 shares during the last quarter. Pendal Group Ltd raised its position in shares of Catalent by 47.6% in the 1st quarter. Pendal Group Ltd now owns 2,421 shares of the company’s stock valued at $126,000 after purchasing an additional 781 shares during the last quarter. Exchange Traded Concepts LLC raised its position in shares of Catalent by 79.7% in the 1st quarter. Exchange Traded Concepts LLC now owns 2,859 shares of the company’s stock valued at $149,000 after purchasing an additional 1,268 shares during the last quarter. Finally, Twin Tree Management LP purchased a new position in shares of Catalent in the 1st quarter valued at approximately $181,000.

Catalent Company Profile

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.

Featured Article: Percentage Gainers

Insider Buying and Selling by Quarter for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.